Cardiovascular effects of medroxyprogesterone acetate and progesterone: a case of mistaken identity?

Potential depot medroxyprogesterone acetate-triggered torsades de pointes in a case of congenital type 2 long QT syndrome. Heart Rhythm (2012) 2.09

Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocr Rev (2012) 1.20

Progesterone improves cognitive performance and attenuates smoking urges in abstinent smokers. Psychoneuroendocrinology (2010) 1.03

Long QTc Syndrome Type 2 Presenting in a Postpartum Patient on Medroxyprogesterone. Case Rep Cardiol (2014) 0.75

ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation (2009) 5.49

ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography). Circulation (2007) 4.66

ACCF/ASNC/ACR/AHA/ASE/SCCT/SCMR/SNM 2009 Appropriate Use Criteria for Cardiac Radionuclide Imaging: A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the American Society of Nuclear Cardiology, the American College of Radiology, the American Heart Association, the American Society of Echocardiography, the Society of Cardiovascular Computed Tomography, the Society for Cardiovascular Magnetic Resonance, and the Society of Nuclear Medicine. J Am Coll Cardiol (2009) 3.51

The rationale and design of the Surgical Treatment for Ischemic Heart Failure (STICH) trial. J Thorac Cardiovasc Surg (2007) 3.45

Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part II: gender differences in presentation, diagnosis, and outcome with regard to gender-based pathophysiology of atherosclerosis and macrovascular and microvascular coronary disease. J Am Coll Cardiol (2006) 3.25

Clinical indications for cardiovascular magnetic resonance (CMR): Consensus Panel report. Eur Heart J (2004) 3.19

Effect of azithromycin treatment on endothelial function in patients with coronary artery disease and evidence of Chlamydia pneumoniae infection. Circulation (2002) 2.73

Integrating complementary medicine into cardiovascular medicine. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents (Writing Committee to Develop an Expert Consensus Document on Complementary and Integrative Medicine). J Am Coll Cardiol (2005) 2.71

Clinical usefulness, angiographic characteristics, and safety evaluation of intracoronary acetylcholine provocation testing among 921 consecutive white patients with unobstructed coronary arteries. Circulation (2014) 2.65

Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part I: gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. J Am Coll Cardiol (2006) 2.57

Total cholesterol content of erythrocyte membranes is increased in patients with acute coronary syndrome: a new marker of clinical instability? J Am Coll Cardiol (2007) 2.56

ACCF/ASNC/ACR/AHA/ASE/SCCT/SCMR/SNM 2009 appropriate use criteria for cardiac radionuclide imaging: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the American Society of Nuclear Cardiology, the American College of Radiology, the American Heart Association, the American Society of Echocardiography, the Society of Cardiovascular Computed Tomography, the Society for Cardiovascular Magnetic Resonance, and the Society of Nuclear Medicine. Circulation (2009) 2.30

High levels of costimulatory receptors OX40 and 4-1BB characterize CD4+CD28null T cells in patients with acute coronary syndrome. Circ Res (2012) 2.26

High prevalence of a pathological response to acetylcholine testing in patients with stable angina pectoris and unobstructed coronary arteries. The ACOVA Study (Abnormal COronary VAsomotion in patients with stable angina and unobstructed coronary arteries). J Am Coll Cardiol (2012) 2.24

ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. J Am Coll Cardiol (2010) 2.23

ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation (2010) 2.14

Prognosis in women with myocardial ischemia in the absence of obstructive coronary disease: results from the National Institutes of Health-National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation (2004) 2.12

Insights from the STICH trial: change in left ventricular size after coronary artery bypass grafting with and without surgical ventricular reconstruction. J Thorac Cardiovasc Surg (2012) 2.10

The economic burden of angina in women with suspected ischemic heart disease: results from the National Institutes of Health--National Heart, Lung, and Blood Institute--sponsored Women's Ischemia Syndrome Evaluation. Circulation (2006) 2.03

Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol (2004) 2.00

Evaluating the quality of research into a single prognostic biomarker: a systematic review and meta-analysis of 83 studies of C-reactive protein in stable coronary artery disease. PLoS Med (2010) 1.89

Pregnancy-associated plasma protein-A (PAPP-A) and cardiovascular risk. Atherosclerosis (2008) 1.76

Ischemia modified albumin is a sensitive marker of myocardial ischemia after percutaneous coronary intervention. Circulation (2003) 1.68

Endothelial dysfunction, inflammation and atherosclerosis in chronic kidney disease--a cross-sectional study of predialysis, dialysis and kidney-transplantation patients. Atherosclerosis (2011) 1.63

Relationship among pregnancy associated plasma protein-A levels, clinical characteristics, and coronary artery disease extent in patients with chronic stable angina pectoris. Eur Heart J (2005) 1.58

Cystatin C and cardiovascular risk. Clin Chem (2009) 1.57

ACCF/AHA clinical competence statement on cardiac imaging with computed tomography and magnetic resonance: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training. J Am Coll Cardiol (2005) 1.56

Clinical indications for cardiovascular magnetic resonance (CMR): Consensus Panel report. J Cardiovasc Magn Reson (2004) 1.54

Pharmacological treatment of chronic stable angina pectoris. Clin Med (2013) 1.51

Fear of dying and inflammation following acute coronary syndrome. Eur Heart J (2011) 1.50

Interleukin-8 is increased in the membrane of circulating erythrocytes in patients with acute coronary syndrome. Eur Heart J (2008) 1.48

New universal definition of myocardial infarction applicable after complex percutaneous coronary interventions? JACC Cardiovasc Interv (2010) 1.46

Heat-shock protein 60-reactive CD4+CD28null T cells in patients with acute coronary syndromes. Circulation (2004) 1.45

Hypoestrogenemia of hypothalamic origin and coronary artery disease in premenopausal women: a report from the NHLBI-sponsored WISE study. J Am Coll Cardiol (2003) 1.44

Soluble CD40 ligand:interleukin-10 ratio predicts in-hospital adverse events in patients with ST-segment elevation myocardial infarction. Thromb Res (2007) 1.43

Obesity, inflammation and brachial artery flow-mediated dilatation: therapeutic targets in patients with microvascular angina (cardiac syndrome X). Cardiovasc Drugs Ther (2012) 1.43

Alteplase treatment affects circulating matrix metalloproteinase concentrations in patients with ST segment elevation acute myocardial infarction. Thromb Res (2005) 1.40

ACCF/AHA clinical competence statement on cardiac imaging with computed tomography and magnetic resonance. Circulation (2005) 1.40

The impact of myocardial flow reserve on the detection of coronary artery disease by perfusion imaging methods: an NHLBI WISE study. J Cardiovasc Magn Reson (2003) 1.35

C-reactive protein elevation and disease activity in patients with coronary artery disease. Eur Heart J (2004) 1.35

Influence of baseline left ventricular function on the clinical outcome of surgical ventricular reconstruction in patients with ischaemic cardiomyopathy. Eur Heart J (2012) 1.33

C-reactive protein, clinical presentation, and ischemic activity in patients with chest pain and normal coronary angiograms. J Am Coll Cardiol (2003) 1.24

Chronic inflammation and increased arterial stiffness in patients with cardiac syndrome X. Eur Heart J (2003) 1.23

The value of estimated functional capacity in estimating outcome: results from the NHBLI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study. J Am Coll Cardiol (2006) 1.23

Prognostic value of global MR myocardial perfusion imaging in women with suspected myocardial ischemia and no obstructive coronary disease: results from the NHLBI-sponsored WISE (Women's Ischemia Syndrome Evaluation) study. JACC Cardiovasc Imaging (2010) 1.21

Neurocognitive function and cerebral emboli: randomized study of on-pump versus off-pump coronary artery bypass surgery. Ann Thorac Surg (2007) 1.18

Left ventricular form and function: scientific priorities and strategic planning for development of new views of disease. Circulation (2004) 1.16

Microvascular dysfunction in cardiac syndrome X: the role of inflammation. CMAJ (2006) 1.15

Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris. Circulation (2004) 1.14

Coronary microvascular dysfunction in the clinical setting: from mystery to reality. Eur Heart J (2012) 1.07

Vitamin D deficiency and endothelial dysfunction in non-dialysis chronic kidney disease patients. Atherosclerosis (2011) 1.05

Intracoronary versus intravenous abciximab administration in patients with ST-elevation myocardial infarction undergoing thrombus aspiration during primary percutaneous coronary intervention--effects on soluble CD40 ligand concentrations. Atherosclerosis (2009) 1.04

Multiple complex stenoses, high neutrophil count and C-reactive protein levels in patients with chronic stable angina. Atherosclerosis (2004) 1.04

Pulse pressure and progression of chronic kidney disease. J Nephrol (2010) 1.03

Brachial artery flow-mediated dilation and myocardial perfusion in patients with cardiac syndrome X. Am J Cardiol (2005) 1.02

Apolipoprotein E genotype and circulating interleukin-10 levels in patients with stable and unstable coronary artery disease. J Am Coll Cardiol (2006) 1.01

A review of methods for assessment of coronary microvascular disease in both clinical and experimental settings. Cardiovasc Res (2008) 0.98

Three dimensional first-pass myocardial perfusion imaging at 3T: feasibility study. J Cardiovasc Magn Reson (2008) 0.98

Systolic 3D first-pass myocardial perfusion MRI: Comparison with diastolic imaging in healthy subjects. Magn Reson Med (2010) 0.98

Inflammation and microvascular dysfunction in cardiac syndrome X patients without conventional risk factors for coronary artery disease. JACC Cardiovasc Imaging (2013) 0.97

Epidemiology of the diabetic heart. Coron Artery Dis (2005) 0.97

Elevated serum neopterin predicts future adverse cardiac events in patients with chronic stable angina pectoris. Eur Heart J (2005) 0.97

Relation of ischemia-modified albumin (IMA) levels following elective angioplasty for stable angina pectoris to duration of balloon-induced myocardial ischemia. Am J Cardiol (2003) 0.97

Pregnancy-associated plasma protein A and its endogenous inhibitor, the proform of eosinophil major basic protein (proMBP), are related to complex stenosis morphology in patients with stable angina pectoris. Circulation (2004) 0.96

Myocardial infarction in the elderly. Aging Dis (2010) 0.96

Inflammatory and anti-inflammatory variable clusters and risk prediction in acute coronary syndrome patients: a factor analysis approach. Atherosclerosis (2006) 0.96

CD4+ CD28 null T cells in coronary artery disease: when helpers become killers. Cardiovasc Res (2008) 0.95

Guidelines for training in Cardiovascular Magnetic Resonance (CMR). J Cardiovasc Magn Reson (2007) 0.94

Ischemia-modified albumin concentrations in patients with peripheral vascular disease and exercise-induced skeletal muscle ischemia. Clin Chem (2004) 0.93

Relation of circulating C-reactive protein to progression of aortic valve stenosis. Am J Cardiol (2005) 0.93

A unicenter, randomized, double-blind, parallel-group, placebo-controlled study of Melatonin as an Adjunct in patients with acute myocaRdial Infarction undergoing primary Angioplasty The Melatonin Adjunct in the acute myocaRdial Infarction treated with Angioplasty (MARIA) trial: study design and rationale. Contemp Clin Trials (2006) 0.92

Predictive value of coronary artery stenoses and C-reactive protein levels in patients with stable coronary artery disease. Atherosclerosis (2008) 0.91

Symptoms, myocardial ischaemia and quality of life in women: results from the NHLBI-sponsored WISE Study. Eur Heart J (2003) 0.90

Relation of nocturnal melatonin levels to C-reactive protein concentration in patients with ST-segment elevation myocardial infarction. Am J Cardiol (2005) 0.90

Comparison of ischemia-modified albumin levels in patients undergoing percutaneous coronary intervention for unstable angina pectoris with versus without coronary collaterals. Am J Cardiol (2004) 0.90

Plasma cystatin C for prediction of 1-year cardiac events in Mediterranean patients with non-ST elevation acute coronary syndrome. Atherosclerosis (2009) 0.89

Marked regional left ventricular heterogeneity in hypertensive left ventricular hypertrophy patients: a losartan intervention for endpoint reduction in hypertension (LIFE) cardiovascular magnetic resonance and echocardiographic substudy. Hypertension (2008) 0.89

Atherosclerotic plaque regression: fact or fiction? Cardiovasc Drugs Ther (2010) 0.89

Women's Ischemic Syndrome Evaluation: current status and future research directions: report of the National Heart, Lung and Blood Institute workshop: October 2-4, 2002: Section 1: diagnosis of stable ischemia and ischemic heart disease. Circulation (2004) 0.88

ACCF 2008 Training Statement on Multimodality Noninvasive Cardiovascular Imaging A Report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training Developed in Collaboration With the American Society of Echocardiography, the American Society of Nuclear Cardiology, the Society of Cardiovascular Computed Tomography, the Society for Cardiovascular Magnetic Resonance, and the Society for Vascular Medicine. J Am Coll Cardiol (2009) 0.88

Association of ischemia-modified albumin and melatonin in patients with ST-elevation myocardial infarction. Atherosclerosis (2007) 0.88

S100 protein and its relation to cerebral microemboli in on-pump and off-pump coronary artery bypass surgery. Eur J Cardiothorac Surg (2004) 0.87

Interleukin-18: interleukin-10 ratio and in-hospital adverse events in patients with acute coronary syndrome. Atherosclerosis (2005) 0.87

Task Force 12: training in advanced cardiovascular imaging (cardiovascular magnetic resonance [CMR]) endorsed by the Society for Cardiovascular Magnetic Resonance. J Am Coll Cardiol (2008) 0.87

Left Ventricular Energy Model Predicts Adverse Events in Women With Suspected Myocardial Ischemia: Results From The NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study. Cardiovasc Diagn Ther (2013) 0.86

C-reactive protein improves risk prediction in patients with acute coronary syndrome, or does it? Eur Heart J (2009) 0.86

Independent and additive predictive value of total cholesterol content of erythrocyte membranes with regard to coronary artery disease clinical presentation. Int J Cardiol (2010) 0.85

N-terminal pro-B-type natriuretic peptide and matrix metalloproteinases in early and late left ventricular remodeling after acute myocardial infarction. Am J Cardiol (2005) 0.85

Serum adiponectin and cardiovascular risk in chronic kidney disease and kidney transplantation. J Nephrol (2010) 0.85

Prognostic value of neopterin levels in treated patients with hypertension and chest pain but without obstructive coronary artery disease. Am J Cardiol (2004) 0.85

Ischemia-modified albumin predicts short-term outcome and 1-year mortality in patients attending the emergency department for acute ischemic chest pain. Heart Vessels (2008) 0.85

A comparative study of markers of inflammation for the assessment of cardiovascular risk in patients presenting to the emergency department with acute chest pain suggestive of acute coronary syndrome. Int J Cardiol (2005) 0.84

Validation of the accuracy of pretest and exercise test scores in women with a low prevalence of coronary disease: the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE) study. Am Heart J (2004) 0.84

Effect of direct-current cardioversion on ischemia-modified albumin levels in patients with atrial fibrillation. Am J Cardiol (2004) 0.84

Mean platelet volume predicts patency of the infarct-related artery before mechanical reperfusion and short-term mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Thromb Res (2009) 0.84

The Who, What, Why, When, How and Where of Vasospastic Angina. Circ J (2015) 0.84

Anti-inflammatory effects of ivabradine in patients with acute coronary syndrome: a pilot study. Int J Cardiol (2012) 0.83

Statin use is associated with a significant reduction in cholesterol content of erythrocyte membranes. A novel pleiotropic effect? Cardiovasc Drugs Ther (2009) 0.83

Pregnancy-associated plasma protein A: Has this biomarker crossed the boundary from research to clinical practice? Drug News Perspect (2009) 0.83

Randomised, double-blind, placebo-controlled trial of ivabradine in patients with acute coronary syndrome: effects of the If current inhibitor ivabradine on reduction of inflammation markers in patients with acute coronary syndrome--RIVIERA trial study design and rationale. Cardiovasc Drugs Ther (2009) 0.83